Allurion Technologies, Inc. said the U.S. Food and Drug Administration has approved its premarket approval application for the Allurion Gastric Balloon System, which includes the Allurion Smart Capsule. The company said the device is intended for patients with a body mass index range of 30 to 40 kg/m² and is administered in an office visit without surgery, endoscopy, or anesthesia.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allurion Technologies Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602230900BIZWIRE_USPR_____20260223_BW930098) on February 23, 2026, and is solely responsible for the information contained therein.
Comments